Janssen Vaccines

Janssen Vaccines is a division of Janssen Pharmaceuticals, which is itself a subsidiary of Johnson & Johnson. Janssen Vaccines is focused on the development, production, and marketing of vaccines to prevent and combat infectious diseases.

History

Janssen Vaccines was established as Crucell in 2000, following the merger of several biotechnology companies. In 2011, it was acquired by Johnson & Johnson and renamed as Janssen Vaccines.

Research and Development

Janssen Vaccines conducts extensive research and development in the field of vaccinology, with a particular focus on diseases such as HIV, Ebola, RSV, and Zika virus. The company's research strategy involves the use of innovative technologies, such as adenovirus-based vectors, to develop novel vaccines.

Products

One of the most notable products of Janssen Vaccines is the Janssen COVID-19 Vaccine, also known as Ad26.COV2.S. This vaccine was granted Emergency Use Authorization by the FDA in February 2021 for the prevention of COVID-19 in individuals 18 years of age and older.

See Also

• Vaccine
• Johnson & Johnson
• Janssen Pharmaceuticals
• Janssen COVID-19 Vaccine

References

<references />

This article is a stub related to pharmacology. You can help WikiMD by expanding it!

Janssen_Vaccines

• Janssen Pharmaceuticals Logo
  Janssen Pharmaceuticals Logo
• 
  Archimedesweg 4, Leiden